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mice, like those generated by Koizumiet al. (2006), were vi-
able and fertile and had preserved neocortical lamina-
tion, with no evidence of subcortical heterotopias. Simi-
lar to Koizumi et al.’s observations, mice mutant for both
DCX and DCLK displayed profound disorganization in
cortical layering and widespread axonal defects in the
corpus callosum, anterior commissure, subcortical fiber
tracts, and internal capsules. However, in contrast to
Koizumi et al.’s results, less severe phenotypes were
noticed in thecorpuscallosum,suggesting potentiallydi-
vergent functions of DCLK, DCLK-DCX-like, CARP, and
CPG16 isoforms in distinct axonal pathways. Interest-
ingly, human neurons deficient in DCX displayed axon-
growth defects similar to those seen in DCLK/DCX
double-null mice. Disruption of DCLK and DCX function
in neurons in vitro led to abnormal dendritic develop-
ment, shorter axons and dendrites, and disrupted axonal
transport of synaptic vesicle proteins during axon
growth. Together, the studies by Koizumi et al. and Deuel
et al. strongly suggest that DCLK and DCX play a syner-
gistic role in neuronal migration and axon growth in em-
bryonic cortex.
The diverse function of DCLK evinced from these three
studies highlights the significance of dynamic rearrange-
ment of microtubule cytoskeleton during corticogenesis
and raises the intriguing question of how the functions of
MAPs, like DCLK and DCX, are orchestrated during dis-
tinct stages of neuronal development in cerebral cortex.
Clearly, understanding the complimentary as well as
unique functions of DCLK and DCX during neurogenesis,
neuronal migration, and neuronal differentiation will be
critical. The differences in DCLK expression noticed in
different domains of the developing cerebral wall in these
three studies suggest that DCLK expression may change
from a restricted expression within the ventricular zone
during early stages of neurogenesis to an increasingly
more restricted expression in postmitotic, migrating
neurons and postmigratory, differentiating neurons as
cerebral cortical development unfolds. It is attractive to
hypothesize that this change in DCLK expression pattern
during development may serve to coordinate neurogen-
esis with appropriate placement and connectivity of neu-
rons. Considering the striking differences in phenotypes
observed between DCX null mice and RNAi-mediated
DCX knockdown, further analysis of neural precursor
proliferation in DCLK, DCX mouse mutants described
by Koizumi et al. and Deuel etal. will be informative. These
mouse models will also be eminently useful in determin-
ing whether DCLK functions to regulate the neuronal fate
of all dividing ventricular progenitors in a generic manner
or whether it differentially regulates the fate of symmetri-
cally and asymmetrically dividing neural precursors.
Though it is evident that DCLK and DCX can synergis-
tically act during neuronal migration and differentiation,
the nature of this interaction remains unclear. Is DCX
a substrate for doublecortin-like kinase and what are
the endogenous substrates for DCLK? Are the microtu-
bule binding activities of DCX and DCLK differentially
regulated? Do different DCLK isoforms have distinct
patterns of developmental coexpression with DCX within
neural progenitors and postmitotic cortical neurons?
Does DCLK interact differentially with known DCX inter-
actors such as AP-1, neurofascin, Lis1, MARK, cJNK,
JIP, neurabin II, and Cdk5? Additionally, the suggestion
that the DCX/DCLK pathway might regulate the vesicle
trafficking (Deuel et al., 2006) needed to support mem-
brane expansions during neuronal motility and process
growth adds a new twist to DCX/DCLK’s function in cere-
bral cortex. While these three studies provide novel and
exciting perspectives on the role of DCLK in cerebral
cortex, how doublecortin domain-containing proteins
orchestrate their multiple functions during cortical devel-
opment remains a challenging question.
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4Cannabinoids in Microglia:
A New Trick for Immune
Surveillance and Neuroprotection
Microglia are the resident immune cells of the brain,
and they are under permanent activity to patrol the
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5cerebral microenvironment. A proper inhibitory feed-
back onto these cells is critical during both intact
and injury conditions. In this issue of Neuron, Elja-
schewitsch and colleagues report that such feedback
is provided by the endogenous cannabinoid anand-
amine and CB1/2 receptor signaling, which ultimately
leads to mitogen-activated protein kinase phospha-
tase-1 (MKP-1) induction. MKP-1 interferes with lipo-
polysaccharide-induced toll-like receptor 4 signaling
and limits brain damage due to exaggeratedmicroglial
reactivity following acute NMDA injury.
There is a constant immune surveillance in the brain by
microglia, which share similar characteristics as macro-
phages. Both macrophages and microglial cells derive
from myeloid progenitors, but microglia are isolated in
the brain parenchyma by the blood-brain barrier (BBB).
Their direct interaction with pathogens is therefore quite
limited, at least in intact brains. It is currently believed
that parenchymal microglia originate from pial macro-
phages and mesenchymal progenitors from the yolk
sac and that they establish themselves in the brain dur-
ing the embryonic stage. However, recent data suggest
the existence of two subpopulations of microglial cells,
each of which may have different origins, i.e., the primi-
tive macrophages from the yolk sac and those newly dif-
ferentiated from monocytes. Over 95% of all microglia
are born after birth and the formation of the BBB, and
there has been an on-going debate regarding the main-
tenance of the microglial population in the adult CNS.
One hypothesis is that adult microglia are maintained
via self-replication or by the division of progenitor cells
already present in the brain. Another hypothesis sug-
gests that circulating monocytes are able to infiltrate
the CNS and differentiate into microglial cells. Concrete
evidence demonstrating the capacity of bone marrow
stem cells (BMSCs) to populate the CNS and differenti-
ate into microglial cells was recently obtained. The prin-
cipal method to study BMSC infiltration into the brain is
to transplant bone marrow cells from a donor animal
into an irradiated host animal. With the use of this model,
many researchers have found donor-derived cells in the
brain of host animals, and BMSCs indeed have the ability
to populate the CNS and differentiate into functional
parenchymal microglia as well as perivascular micro-
glia (Massengale et al., 2005; Simard and Rivest, 2004;
Vallieres and Sawchenko, 2003).
The second debated concept regarding macroglia
relates to their states of being either resting, alerted, or
activated. Obviously, these states largely depend on the
tools used to evaluate such an activity, and the shape
of the cells was regularly used as a reference. The
term ‘‘amoeboid cells’’ was previously used as an index
of activation, but it is now believed to be a state of differ-
entiation rather than activation. Indeed, amoeboid cells
are monocytic cells in the process of being differenti-
ated into ramified microglia. Recruitment of monocytes
is particularly active in various models of CNS injury
that are accompanied with BBB leakage. On the other
hand, novel imaging technologies have markedly im-
proved our knowledge on this matter. By using in vivo
two-photon imaging in neocortex, Nimmerjahn and col-
leagues found that microglial cells are highly active intheir presumed resting state, continually surveying their
microenvironment with extremely motile processes and
ramifications. An immediate and focal activation of mi-
croglia is also detected following BBB disruption (Nim-
merjahn et al., 2005). Such a switch in their behavior
from patrolling to shielding of the injured site is depen-
dent on ATP/P2Y G protein-coupled receptor signaling
mechanisms (Davalos et al., 2005). The high baseline
motility of microglial processes may thus reflect the fluc-
tuation of the ATP concentration in the surrounding tis-
sue (Davalos et al., 2005).
The characterization of the toll-like receptor (TLR)
family has also greatly contributed to a better under-
standing of the natural innate immune response by mi-
croglial cells. The Toll protein was first discovered as
an essential molecule for the establishment of the dorso-
ventral axis in theDrosophila embryo. TLRs are mamma-
lian homologs of this protein, which are expressed at the
surface of a specific group of immune cells known as the
antigen-presenting cells (APCs), in the brain microglia.
These cells are rapidly activated by pathogens that
bind to specific TLRs. A large family of TLRs, consisting
of at least 12 highly homologous TLRs (10 in human and
12 in the mouse), has been characterized. The extra-
cellular domains of all TLRs are comprised of 18 to 31
leucine-rich repeats and are very divergent from one an-
other, indicating that these receptors recognize different
molecules. The cytoplasmic domain of these proteins
is highly similar to the cytoplasmic portion of the inter-
leukin-1 receptor (IL-1R), and is therefore named the
Toll/IL-1R (TIR) homologous region. It is now proposed
that the various TLRs are key to the selective recogni-
tion of the major components produced by bacteria
and viruses. These components are called pathogen-
associated molecular patterns (PAMPs). PAMPs from
Gram-positive bacteria are recognized by TLR2 con-
jugated to TLR6 or TLR1, double-stranded RNA (dsRNA)
viruses are recognized by TLR3, LPS from Gram-
negative bacteria binds to TLR4, flagellin to TLR5, and
CpG bacterial and viral DNA triggers signaling via
TLR9. Single-stranded RNAs (ssRNAs) from viruses
(e.g., HIV-1 and influenza) are the physiological ligands
for TLR7 and TLR8, whereas uropathogenic bacteria ac-
tivate TLR11. It is also believed that TLR1, 2, 4, 5, 6, and
11 recognize extracellular bacterial components, while
TLR3, 7, 8, and 9 are sensors for intracellular PAMPs in
the phagosome (e.g., CpG DNA, ssRNA, and dsRNA).
Human TLR10 has no mouse counterpart, and mouse
TLR11–13 have no known ligands yet.
Because of the presence of the TIR domain, TLRs
activate signaling pathways that are similar to those en-
gaged by IL-1. The TIR domain can interact with MyD88
(Figure 1). This adaptor protein has an amino-terminal
death domain (DD) that associates with the IL-1R-asso-
ciated kinase (IRAK), a serine kinase that activates an-
other adaptor molecule—tumor necrosis factor (TNF) re-
ceptor (TNFR)-associated factor 6 (TRAF6). Recruitment
of TRAF6 leads to the activation of multiple kinases,
which ultimately free NF-kB for triggering transcriptional
activation of proinflammatory genes (TNF-a, IL-1b, IL-
12p40,.). There are also MyD88-independent signaling
events involving a different subset of accessory pro-
teins, such as Toll/IL-1R domain-containing adaptor-
inducing IFNb (TRIF), TRIF-related adaptor molecule
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6Figure 1. Schematic Illustration of the Hypothetical Interaction between Anandamine (AEA)/CB1/2 Receptor Signaling and the MyD88-
Independent Signal Transduction Pathway Engaged by the Binding of Lipopolysaccharide to Its Cognate Toll-Like Receptor 4
The high-affinity extracellular complex includes CD14 and MD-2. Such an interaction leads to the classical proinflammatory pathway involving
MyD88, multiple kinases, and NF-kB, which triggers cytokine gene expression (e.g., TNF-a). TLR4 activation is also able to stimulate a different
subset of cytokines (e.g., type I interferons) through a MyD88-independent pathway with the participation of the adaptor proteins TRAM, TRIF,
and the transcription factors IRF3/7. Biosynthesis of costimulatory molecules (e.g., iNOS) largely depends on IRF3-induced IFNb. The MyD88-
independent signal transduction pathway may then be an indirect target of AEA, because Eljaschewitsch and colleagues found that CB1/2 re-
ceptor signaling and MKP-1 synthesis (through histone H3 phosphorylation) were able to markedly suppress iNOS gene expression and NO pro-
duction in microglia. Because LPS-induced TNF-a release remained essentially unchanged by modulating the cannabinoid system (data not
shown), it can be concluded that the MyD88-dependent route of NF-kB activation is not involved in the inhibitory feedback of AEA on microglia.(TRAM), and the transcription factors IRF3/7. The latter
stimulate transcription of the type I interferons (IFNa
and b), which then cause production of costimulatory
molecules (iNOS, IP10, MHC class II,.).
Interaction between LPS and TLR4 has been widely
studied in microglia both in vivo and in vitro. Systemic
challenge with the endotoxin triggers transcriptional
activation of inflammatory genes in microglial cells
throughout the brain parenchyma. Such widespread mi-
croglial reactivity to LPS is dose and time dependent.
Some genes are induced very rapidly (e.g., IkBa,
TNF-a, IL-1b, CD14), while others take several hours to
days to be detected (e.g., complement proteins). Direct
injection of LPS into the CNS parenchyma also causes
a strong and time-dependent transcriptional activation
of inflammatory genes in microglial cells ipsilateral to
the site of injection (Nadeau and Rivest, 2002). Such a ro-
bust and transient inflammatory response by microglia
is not associated with neuronal damages or demyelin-
ation (Nguyen et al., 2002). Inhibition of these activated
cells would seriously compromise the natural immune
surveillance of the brain and prevent proper elimination
of pathogenic substances in the cerebral microenviron-
ment. If left unchecked, however, microglia cause dam-
aging inflammatory responses reminiscent of neurode-
generative disorders (Nadeau and Rivest, 2003; Soulet
and Rivest, 2003).
In this issue ofNeuron, Eljaschewitsch and colleagues
(Eljaschewitsch et al., 2006) report a new mechanism
that provides an inhibitory feedback on microglia duringboth intact and degenerating conditions. They first show
that absolute endogenous anandamine (AEA) concen-
trations increase in the brain of patients suffering of mul-
tiple sclerosis (MS), a disease with a clear immune etiol-
ogy. Although the AEA levels were significantly higher in
silent MS patients over the control, active MS patients
had twice as many AEA concentrations than silent MS
individuals. Coadministration of NMDA and the BV-2 mi-
croglial cell line also increased AEA levels in brain slice
cultures, whereas exogenous AEA prevented microglia-
induced neuronal damages in the presence of both
NMDA and oxygen-glucose deprivation conditions. Of
great interest here is the result that although the pres-
ence of BV-2 cells in the culture system was not by itself
causing neuronal damages, these cells were needed for
AEA-induced neuroprotection following NMDA insults.
CB2 was found to be a key receptor mediating these
neuroprotective properties of the endocannabinoid sys-
tem in microglia. Once again the presence of BV-2 cells
in culture hippocampi did not lead to neurodegenera-
tion, but CB1 and CB2 receptor antagonists were toxic
to neurons. It can be concluded from these data that
constitutive CB receptors restrict microglial activity to
a proper immune surveillance and inhibiting the canna-
binoid system would result in a loss of control of these
immune cells in the CNS environment.
Such a mechanism fits very well with the ability of
these cells to patrol the cerebral milieu where microglia
are clearly beneficial to the neuronal elements. The bind-
ing of AEA to their cognate CB receptors is therefore one
Previews
7of the mechanisms restricting microglia activity under
basal conditions. This is also the case in inflamed condi-
tions, because AEA was able to prevent LPS-induced ni-
tric oxide (NO) production and iNOS gene expression in
isolated BV-2 cells as well as coculture of brain tissue
with BV-2 cells. It is important to note that AEA is unlikely
to modulate the classical inflammatory reaction to LPS
(Figure 1). IL-6 levels were not completely abolished,
while AEA failed to change TNF-a production. It will be
critical in future studies to investigate how CB receptor
signaling interferes with TLR4 signal transduction path-
ways and NF-kB/IRF activity in microglia (see below).
In a series of very elegant studies, Eljaschewitsch and
colleagues investigated the intracellular signaling path-
ways mediating the effects of AEA in BV-2 cells. They ob-
served that the endogenous cannabinoids set microglia
into a state of alert by a rapid MAPK phosphorylation and
prevent overactivation in the presence of second stimu-
lus. Indeed, MEK phosphorylation is reduced and Erk1/2
dephosphorylation takes place after AEA incubation
in LPS-activated BV-2 cells. This is associated with a
rapid induction of the mitogen-activated protein kinase-
phosphatase 1 and 2 (MKP-1 and MKP-2). Here, MKP ex-
pression was not necessarily a direct consequence of
the MAPK activation; although AEA alone can activate
the MAPK, it switched off this pathway by rapidly upreg-
ulating MKP-1 induction following exposure to LPS. The
combined treatment of LPS and AEA (not LPS and AEA
alone) enhanced histone H3 phosphorylation on the
MKP-1 gene sequence. Finally, these authors show
that AEA was able to inhibit BV-2 cells in a CB1/2- and
MKP-1-dependent manner and that MKP-1 can be found
in microglial cells of MS patients. These data provide the
first direct evidence that the CB receptors in microglia
are coupled to Erk activation in regulating MKP-1 gene
expression following histone H3 phosphorylation.
The authors reached the conclusion that the endo-
cannabinoid AEA induces histone H3 phosphorylation,
MKP-1 gene expression, and subsequent Erk1/2 de-
phosphorylation in activated (e.g., LPS) but not in rest-
ing microglia, which in turn abolishes NO release and fi-
nally leads to neuroprotection. It is however important to
keep in mind that all of these studies were performed in
culture systems where brain slices were exposed to BV-
2 cells and in one occasion to primary cultures of micro-
glia. Direct interaction of these immune cells with CNS
tissues taken from another group of animals may not
represent the real situation taking place in vivo. Ex-
ogenous microglia may be under a different state of im-
mune activation, which may be quite different from
endogenous cells behind the BBB. This may modify
TLR4 expression, the affinity to its ligand, LPS signaling,
and expression of a subset of genes. Also, how these
exogenous microglia interfere with their endogenous
counterparts still remains to be determined.
The role of microglial cells in neurodegenerative disor-
ders remains a matter of great controversy and debate
at the moment. It is clear that LPS-induced proinflam-
matory signaling in microglia is a natural response that
is unlikely to be detrimental to neurons and other cells
of the CNS. In contrast, a proper immune response
may set the conditions for swiftly eliminating pathogens
in cases of cerebral infection, phagocyting cell debris
after injuries, and improving brain repair. Recent datasupport this concept, because inhibition of microglia
and TNF-a production was found to cause more dam-
ages following acute excitotoxicity (Turrin and Rivest,
2006), delay in remyelination, and inhibit recruitment of
progenitors (Arnett et al., 2001). Genes encoding innate
immune proteins are induced not only by PAMPs, but
also in response to brain injuries and during a variety
of neurodegenerative disorders. What comes first (in-
flammation or cellular degeneration) remains largely un-
known, and the role of such an innate immune/inflam-
matory response in the cerebral tissue has yet to be
fully unraveled. It is clear that sustained and unregulated
inflammatory reactions are detrimental to neurons,
though the acute release of proinflammatory molecules
may instead play a leading role in protecting neurons
against invading pathogens and restoring homeostasis
after the storm. The direction that the inflammatory re-
sponse is taking and the appropriate inhibitory feedback
on microglia may consequently be crucial for determin-
ing the ultimate outcome of these events in the CNS.
As shown by Eljaschewitsch and colleagues in this is-
sue, cannabinoid receptor signaling and MKP-1 gene ex-
pression in microglia may well be the ultimate trick for
allowing these cells to either protect or contribute to neu-
rodegeneration following acute brain damage. Future
experiments are nevertheless needed to specifically de-
fine the physiological relevance of such a system in the
mature as well as developing brain in an in vivo context.
Moreover, how cannabinoid receptors interact with
TLR4 signaling in microglia remains to be determined.
It is possible that such an interaction does not involve
the classical LPS-TLR4-NF-kB pathway, but the MyD88-
independent signal transduction system. Although AEA
had very clear effects on NO release and iNOS gene ex-
pression in BV-2 cells, cytokine levels were either not
changed (e.g., TNF-a) or moderately modified (e.g.,
IL-6) in the presence of endogenous and exogenous can-
nabinoids. This supports the MyD88-independent set of
events and the subsequent IFN release, which is a key
step for iNOS gene expression and NO biosynthesis
(Schilling et al., 2002). As depicted by Figure 1, this path-
way may be the direct target of the so-called inhibitory
feedback of the AEA/CB1/2, Erk, and MKP-1 cascade.
MKP-1 in causing Erk dephosphorylation and switching
off MAPK would then lead to IFN gene repression. It is
also tempting to propose a direct MKP-1/IRF interaction
and dephosphorylation, such as in the case of Erk1/2.
These events together are powerful novel mechanisms
to prevent the production of type I IFNs and their costi-
mulatory molecules (e.g., iNOS) without interfering with
the MyD88-dependent signal transduction pathway
and cytokine gene expression. Although still speculative
at this point, these data open the door for a potentially
new treatment to inhibit specific signaling events with
no side effects on those that might have neuroprotective
properties in microglia. Of interest is the fact that exoge-
nous cannabinoids (e.g., marijuana) seem to improve re-
covery, decrease frequency in relapsing, and delay de-
myelination in MS patients. These frequently discussed
beneficial assets of marijuana have to be validated with
in-depth studies, but MyD88-independent pathways
may well be the indirect target of cannabis through
CB1/2 receptors and MKP-1 induction in macroglia and
infiltrating macrophages. A new trick, yes indeed!
GABAergic interneurons remain in oscillatory synchrony
Figure 1. Diverse Mechanisms Underlying Interneuronal Synchrony
(A) Simplified wiring diagram showing autaptic and reciprocal con-
nections between FS interneurons (red) and pyramidal cells (black).
(B) Homogenization and synchronization of firing by shunting in-
hibition in interneuronal networks. When the reversal potential for
GABAergic events (E, dotted lines) is above the resting membrane
potential, but below spike threshold, GABAergic conductances
(G, lower trace) can decelerate strongly activated neurons (upper
trace), while accelerating the firing in weakly activated neurons
(middle trace). Computer simulation of Hodgkin-Huxley kinetics in
a single-compartment model.
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GABAergic interneurons play a key role in orchestrat-
ing cortical network oscillations. In this issue of Neu-
ron, two studies (Bacci and Huguenard and Vida
et al.) identify how networks of fast-spiking interneur-
ons can enhance the regularity, precision, and robust-
ness of their own rhythmicity via individual and collec-
tive self-innervation.
Neuronal networks of the mammalian cortex are com-
prised of two main classes of neurons: principal cells
and GABAergic interneurons. Whereas principal cells
excite other neurons to generate action potentials, the
timing of those action potentials is to a large extent
controlled by GABAergic interneurons. During active
network states, characteristic oscillations in several fre-
quency ranges emerge, at least partly due to the exten-
sive feedback coupling between principal neurons and
GABAergic interneurons. Some of the best studied of
these network oscillations are the so-called gamma os-
cillations (30–100 Hz), which have been linked to cogni-
tive processing (see Whittington and Traub, 2003). Dur-
ing gamma oscillations, fast-spiking (FS) GABAergic
interneurons maintain a regular rhythm, tightly coupled
to the population oscillation, whereas pyramidal neu-
rons fire at a slower pace and are more loosely cou-
pled to the on-going rhythm. How can the network of
in the presence of barrages of other on-going synaptic
activity? By studying isolated GABAergic interneurons
in brain slices and simulating their interactions, two
new mechanisms have been identified that help achieve
this (Bacci and Huguenard, 2006; Vida et al., 2006).
First, Bacci and Huguenard show that self-innerva-
tion, or so-called ‘‘autaptic’’ transmission, has the ca-
pacity to enhance spike fidelity in individual FS inter-
neurons (Figure 1A). Anatomically, it is well established
that FS interneurons innervate themselves (Tamas
et al., 1997). These autaptic connections provide a brief
GABA(A) receptor-mediated conductance following
each action potential (Bacci et al., 2003). The function
of this conductance has remained unclear. Now, Bacci
and Huguenard link this conductance to network oscilla-
tions by showing an enhanced regularity and spike-tim-
ing precision mediated by these autaptic connections
(Bacci and Huguenard, 2006). Blocking GABA(A) recep-
tors dramatically increased spike jitter in interneurons,
and the elegant use of dynamic clamp (Prinz et al.,
2004) to mimic the autaptic connections was sufficient
to restore the precision in spike timing. The use of dy-
namic clamp in this study was justified because autaptic
connections target the somatic domain. Hence, adding
an artificial conductance through the recording elec-
trode at the soma can closely mimic the effect of synap-
tic input. There is a difficulty in extrapolating to the func-
tional importance of these autapses in active networks,
but Bacci and Huguenard also show that autaptic
effects on both regularity and spike-timing precision
are robust against synaptic noise, suggesting that the
